Summit Partners Public Asset Management’s Cidara Therapeutics CDTX Stock Holding History

Summit Partners Public Asset Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-477,527	Closed	-$105M	–	157
2025 Q4	$105M	Buy	477,527 +347,527	+267%	+$56.2M	2.19%	11
2025 Q3	$12.4M	Buy	+130,000	New	+$8.3M	0.26%	96

Summit Partners Public Asset Management's CDTX Position: Q1 2026 in Review

Summit Partners Public Asset Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 477,527 shares — an estimated $105M sold.

Summit Partners Public Asset Management first reported a position in CDTX in Q3 2025 and held it in 2 quarters. The position peaked at $105M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Summit Partners Public Asset Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Summit Partners Public Asset Management sold 477,527 Cidara Therapeutics shares in Q1 2026, an estimated $105M.
Summit Partners Public Asset Management first reported a position in Cidara Therapeutics in Q3 2025 and held it in 2 quarters.
Summit Partners Public Asset Management's Cidara Therapeutics position peaked at $105M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Summit Partners Public Asset Management's 13F filing for Q1 2026, filed 15 May 2026.